Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion type Assertion NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_head.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion description "[Combination trials of ruxolitinib and novel anti-fibrosing agents such as PRM-151 represent an attempt to address therapeutic limitations of JAK2 inhibitors such as reversal of bone marrow fibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion evidence source_evidence_literature NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion SIO_000772 25189730 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion wasDerivedFrom befree-2016 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.
- NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_assertion wasGeneratedBy ECO_0000203 NP1217012.RAo33WnxnUpuMGROrna4IkC93EUblB1ZX7lxnhBZ5wDow130_provenance.